Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clarinex extension

This article was originally published in The Tan Sheet

Executive Summary

FDA has approved Clarinex-D 12-Hour extended release tablets, Schering announces Feb. 1. The new formulation (desloratadine 2.5 mg/pseudoephedrine sulfate 120 mg) features a bi-layer tablet delivery system to control the release of the pseudoephedrine. The drug will be available in March, in time for allergy season, Schering notes. Separately, Claritin sales decreased 29% to $54 mil. during the fourth quarter of 2005, the company reports in an earnings call Jan. 30. Decreased Claritin-D (loratadine/pseudoephedrine) sales were attributed to PSE retail restrictions. Lower Claritin revenues, as well as a dip in sales of other pseudoephedrine-containing products contributed to a 9% decline in Consumer Health Care sales from the prior-year period to $198 mil. for the quarter. Adjusted net sales for the firm overall increased 13% to $2.7 bil. in the quarter, signaling the firm's move "from survive mode into thrive mode," CEO Fred Hassan states...

You may also be interested in...



Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty

The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel